Gemcitabine reduces MDSCs, tregs and TGFβ-1 while restoring the teff/treg ratio in patients with pancreatic cancer

BACKGROUND: Cancer immunotherapy can be potentiated by conditioning regimens such as cyclophosphamide, which reduces the level of regulatory T cells (tregs). However, myeloid suppressive cells are still remaining. Accordingly to previous reports, gemcitabine improves immune status of cancer patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Eriksson, Emma, Wenthe, Jessica, Irenaeus, Sandra, Loskog, Angelica, Ullenhag, Gustav
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5041438/
https://www.ncbi.nlm.nih.gov/pubmed/27687804
http://dx.doi.org/10.1186/s12967-016-1037-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5041438/
https://www.ncbi.nlm.nih.gov/pubmed/27687804
http://dx.doi.org/10.1186/s12967-016-1037-z

Ejemplares similares